UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 20, 2005
The Medicines Company
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-31191 04-3324394
------------------------------ ---------------- ------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
8 Campus Drive
Parsippany, New Jersey 07054
------------------------------------------------ -------------------------
(Address of Principal Executive Office (Zip Code)
Registrant's telephone number, including area code: (973) 656-1616
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On July 20, 2005, The Medicines Company (the "Company") announced its
financial results for the quarter ended June 30, 2005. The full text of the
press release issued in connection with the announcement is furnished as Exhibit
99.1 to this Current Report on Form 8-K.
The information in this Form 8-K (including Exhibit 99.1) shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934
(the "Exchange Act") or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference in any filing under the
Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits
(c) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be
furnished, and not filed:
99.1 Press Release dated July 20, 2005 entitled "The Medicines
Company Reports Second Quarter and First Half 2005
Financial Results."
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
THE MEDICINES COMPANY
Date: July 20, 2005 By: /s/ Steven H. Koehler
---------------------
Steven H. Koehler
Senior Vice President and
Chief Financial Officer
Exhibit Index
Exhibit No. Description
----------- -----------
99.1 Press release dated July 20, 2005 entitled
"The Medicines Company Reports Second
Quarter and First Half 2005 Financial
Results."